EN | TR
E-ISSN: 3061-9947
Non-infectious Complications in Patients with Allogeneic Hematopoietic Stem Cell Transplantation- Single Center Experience from Eastern Anatolia
PDF
Cite
Share
Request
Original Article
VOLUME: 55 ISSUE: 2
P: 109-115
2022

Non-infectious Complications in Patients with Allogeneic Hematopoietic Stem Cell Transplantation- Single Center Experience from Eastern Anatolia

Acta Haematol Oncol Turc 2022;55(2):109-115
DOI: 10.5505/aot.2022.92668
Sevtap Karaman 1
Ahmet Sarıcı 2
Mehmet Ali Erkurt 1
Soykan Biçim 1
Emine Hidayet 1
Ahmet Kaya 1
İrfan Kuku 1
Saim Yologlu 3
Ilhami Berber 1
Emin Kaya 1
Mustafa Özgül 1
1. Malatya Training and Research Hospital, Department of Internal Medicine, Malatya, Turkey
2. Inonu University, Faculty of Medicine, Department of Hematology, Malatya
3. Inonu University, Turgut Ozal Medical Center, Department of Biostatistics and Medical, Malatya, Turkey
4.
No information available.
No information available
Received Date: 2021-10-06T10:42:35
Accepted Date: 2022-08-01T05:54:56
PDF
Cite
Share
Request

Abstract

INTRODUCTION

The aim of this study was to investigate late non-infectious complications in patients with allogeneic hematopoietic stem cell transplantation (HSCT).

METHODS

The records of 143 patients who underwent allogeneic HSCT between 01.02.2011 and 31.12.2018 in Inonu University Turgut Ozal Medical Center Department of Hematology were retrospectively reviewed.

RESULTS

In our study, late non-infectious complications were seen in 68 % of the patients. Graft Versus Host Disease (GVHD) was observed in 43 patients (33%) %. The most common GVHD involvement sites were skin and liver. It was determined that the number of CD 34 (+) cells had a significant effect on the development of chronic GVHD (p=0,01) and late stage complications (p=0,016). Chronic GVHD and late complication rates were found to be lower in the group given high CD 34 (+) cell count. When the patients were grouped according to the preparation regimens, statistically significantly more complications were observed at the rate of 78.8% in the patients in the myeloablative regimen group (p=0.005). It was observed that the rate of recurrence of the primary disease, renal complications and neurological complications was higher in the 90-120th days after transplantation. Ocular and GVHD complications were more likely to develop later. It was observed that endocrine complications were encountered equally in both early and late periods.

DISCUSSION AND CONCLUSION

It was seen that, late complications were common in patients who underwent allogeneic HSCT and these complications were mostly related to GVHD and GVHD treatment.